1. Introduction {#sec1}
===============

The therapeutic strategy for stage IIIA non-small cell lung cancer (NSCLC) with ipsilateral mediastinal nodal metastasis (N2) are the subject of ongoing debate. Surgery alone has been associated with a poor outcome in some studies [@bib1], [@bib2]. Induction chemotherapy followed by surgical resection has found general acceptance. Induction chemotherapy is performed to reduce the risk of micrometastatic progression and improve the resectability of NSCLC [@bib3]. However, the long-term prognosis of induction chemotherapy followed by surgery for N2 NSCLC remains unclear. The aim of this retrospective study was to analyze the long-term prognosis of N2 NSCLC patients who undergo induction chemotherapy followed by surgery and to identify the prognostic factors, based on PROCESS Guidelines [@bib4].

2. Patients and methods {#sec2}
=======================

We retrospectively reviewed th[e records]{.ul} of 31 N2-NSCLC patients who underwent induction chemotherapy followed by surgery at National Hospital Organization, Okinawa National Hospital between January 1999 and December 2013.Twenty-nine of the patients with biopsy-confirmed N2 disease. N2 disease was clinically confirmed based on a CT scan (n = 2), a CT scan combined with positron emission tomography (PET) (n = 10), or a CT scan combined with Gallium scan (n = 19).

The objective tumor response was evaluated using CT. A complete response (CR) was defined as 100% regression of the tumor, and a partial response (PR) was defined, according to the Response Evaluation Criteria in Solid Tumors (RECIST guideline version1.1), as tumor regression of \>30%.

The pathological effect of induction chemotherapy was classified according to the General Rule for Clinical and Pathological Record of Lung Cancer, sixth edition [@bib5] as a pathologically complete response (complete cancer cell death; Ef 3), a major response (fewer than one third of cancer cells were viable; Ef 2) or a minor response (more than one third of cancer cells were viable; Ef 1).

Overall survival (OS) was calculated from the date of the surgery and analyzed using the Kaplan-Meier method and the log-rank test. A multivariate analysis was performed using a Cox regression model. P values of \<0.05 were considered to indicate statistical significance. All of the data were analyzed using the JMP software, program (version 12, SAS Institute, Cary, NC, USA).

3. Results {#sec3}
==========

3.1. Patient characteristics {#sec3.1}
----------------------------

The study population included 24 males and 7 females, with a median age of 66 years (range, 46--78 years). All of the patients had a performance status (PS) score (Eastern Cooperative Oncology Group \[ECOG\]) of 0 or 1. The tumors included 15 adenocarcinomas, 14 squamous cell carcinomas (Sq), and 2 adenosquamous carcinomas. Their characteristics are shown in [Table 1](#tbl1){ref-type="table"}.

3.2. Clinical response {#sec3.2}
----------------------

Sixteen patients received cisplatin plus docetaxel, 12 received carboplatin plus paclitaxel, 1 received gemcitabine plus vinorelbine, 1 received cisplatin plus docetaxel and cisplatin plus gemcitabine, and 1 received cisplatin plus gemcitabine. The median numbers of courses of induction chemotherapy was 2 (range, 1--5). The clinical response to the induction chemotherapy was CR in 1 patient, PR in 18, SD in 11 patients, and PD in 1 patient. Concerning the clinical stage (yc), downstaging was induced in 7 (22.6%) of the 31 patients.

3.3. Surgery {#sec3.3}
------------

The median time from the induction chemotherapy until surgery was 35 days (range, 21--68 days). The mean operative time was 384 min (range, 214--794 min), and the mean blood loss was 465 ml (range, 50--1732 ml). The surgical procedures included lobectomy (n = 25), bilobectomy (n = 3), lobectomy with bronchial plasty (n = 1), and lobectomy with pulmonary arterial plasty (n = 2). There were no cases of operative mortality. Complete tumor resection with microscopically negative margins was achieved in 30 cases. The resection was incomplete in one patient due to the presence of microscopic residual cancer cells in the parietal pleura. Complete resection was performed in 96.8% of the patients. The morbidity and 30-day mortality rates were 9.35 and 0%, respectively. The morbidity included prolonged air leakage in 2 patients and bronchial stamp fistula in 1 patient.

3.4. Pathological response {#sec3.4}
--------------------------

With regard to the pathological effects of induction chemotherapy, 4 (12.9%) patients had an Ef 3 response, 3 (9.6%) had an Ef 2 response and 24 (77.4%) had an Ef 1 response. With regard to the pathological stage (yp), downstaging was induced in 9 (29%) of the 31 patients. The pathological stage (yp) of 22 patients (70.7%) corresponded with the clinical stage (yc), while the pathological stage of 4 patients was worse than the clinical stage.

3.5. Prognosis and recurrence {#sec3.5}
-----------------------------

The median follow-up period was 7.89 years. The median disease-free interval (DFI) was 13.9 months. The global 5-year overall survival rate (OS) was 58.7% ([Fig. A](#fig1){ref-type="fig"}); the 5-year OS rates in the non-SQ and SQ patients were 49.3% and 70.7% respectively (p = 0.983) ([Fig. B](#fig1){ref-type="fig"}), while the 5-year OS rates in the patients with an Ef 1, Ef 2 and EF3 response were 61.3, 66.6, and 37.5%, respectively (p = 0.238) (Fig. C). The 5-year OS rates in the patients with and without pathological downstaging were 85.7 and 52.4%, respectively (p = 0.696) (Fig. D). The recurrence rate was 74.2%. The univariate analysis of the clinical and pathological characteristics associated DFI and OS are shown in [Table 2](#tbl2){ref-type="table"}. Although none of the factors were significantly associated with OS, a significant association was found between the tumor histology and DFI on (Sq, 23.5 months; Non-Sq, 6.7 months; p = 0.041). At the final follow-up examination, 4 patients were alive and free of cancer and 5 patients were alive with cancer. Eighteen patients died of cancer and 4 patients died of other causes (second primary lung cancer \[n = 2\], interstitial pneumonitis \[n = 1\], and unknown cause \[n = 1\]).

4. Discussion {#sec4}
=============

This study evaluated the long-term outcomes of induction chemotherapy followed by surgery in patients with N2 NSCLC. Induction chemotherapy was initiated during the 1980s. Since then, several meta-analyses have reported that induction chemotherapy significantly improves survival in comparison to surgery alone [@bib6], [@bib7], [@bib8], [@bib9]. Furthermore, several factors have been previously reported to predict a favorable long-term outcome in patients who are treated with a multimodal approach, including the clinical and pathological response to chemotherapy, the ability to completely resect the tumor and the mediastinal lymph nodes, and the complete clearance of N2 disease [@bib3], [@bib10], [@bib11], [@bib12]. In the current study, patients with squamous cell carcinoma had a significantly higher DFI than patients with adenocarcinoma. To the best of our knowledge, other previous studies involving induction chemotherapy failed to find such an association. In general, the degree of differentiation, and lymphatic and blood vessel invasion are generally related to the risk of recurrence. However, the current study could not find an association because it was impossible to precisely evaluate cancer tissue that was damaged by induction chemotherapy. Thus, there may be some bias in the results related to the histologic subtype, and to lymphatic and blood vessel invasion. A greater accumulation of such patients or a prospective trial is needed to identify the prognostic value of the histological subtype.

Most previous studies have involved short-to medium-term follow-up periods, while those that have investigated the long-term outcomes have lacked statistical power [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18]. On the other hand, some studies with long-to medium-term follow-up periods demonstrated 5-year OS rates of 35--43% in patients with N2 NSCLC who received induction chemotherapy [@bib3], [@bib12], [@bib19]. Our survival data were much better. However, the median DFI and the recurrence rate in the present study were 13.9 months and 74.2%, respectively. This was similar to the results of previous studies [@bib3], [@bib12], [@bib19]. This means that treatments for recurrence, such as chemotherapy or radiation therapy, contributed to improving the long-term prognosis of the patients in the current study. In recent years there has been remarkable progress in chemotherapy for recurrent NSCLC, including driver mutation and molecular-targeted therapy. We hypothesize that this progress will continue to improve the prognosis of patients with recurrent NSCLC. Furthermore, progress in relation to the development of induction chemotherapeutic drugs may improve curability.

Although the various incidences of postoperative morbidity and mortality after induction chemotherapy have been reported in previous studies [@bib14], [@bib15], [@bib18], the frequency of morbidity was low and there were no cases of perioperative mortality in our series.

Although the efficacy of induction chemoradiation therapy in N2 NSCLC has recently been established [@bib20], [@bib21], [@bib22], one study failed to find a survival benefit in comparison to induction chemotherapy [@bib23]. A greater accumulation of such patients or a prospective trial is needed to identify the efficacy of concurrent chemoradiation therapy in comparison to induction chemotherapy for N2 NSCLC.

The present study is associated with some limitations. First, this was a single center, retrospective study. Second, the sample size was small. Third, with the exception of 2 patients, all of the patients were diagnosed with N2 based on imaging findings; however, the N2 mediastinal lymph nodes were affected by induction chemotherapy in all of the patients. Therefore, although the potential risk is low, it is possible the incidence of N2 was overestimated. Despite these limitations, our survival data were much better than those of past reports. However, prospective randomized trials are needed to verify the long-term outcomes of induction chemotherapy followed by surgery for N2 NSCLC.

In conclusion, although the chance that induction chemotherapy followed by surgery will achieve a permanent cure in patients with N2 NSCLC is not high, the use of this multimodal treatment in patients with recurrent disease achieves a greater improvement in the long-term prognosis than conventional therapy.
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![(A) The global 5-year overall survival rate. (B) The 5-year OS rates in the non-Sq and Sq patients. (C) The 5-year OS rates in the patients with an Ef 1, Ef 2 and Ef 3 response. (D) The 5-year OS rates in the patients with and without pathological downstaging.](gr1){#fig1}

###### 

Patient characteristics.

Table 1

  Characteristics                                                                No. of patients
  ------------------------------------------------------------------------------ -----------------
  Gender                                                                         
   Male/Female                                                                   24/7
  Age, years, median(range)                                                      64 (46--78)
  Smoking status                                                                 
   Never/Former/Current                                                          2/10/19
  Tumor histology                                                                
   Sq/Non-Sq                                                                     14/17
  N2 status assessment method                                                    
   CT/Biopsy/CT&PET-CT/CT& Gallium scan                                          2/2/8/19
  The number of N2 lymph nodes                                                   
   Single/Multiple                                                               12/19
  Tumor size,mm, median (range)                                                  42 (12--1000)
  Serum tumor marker                                                             
   Increase/Decrease                                                             22/9
  The number of times of Induction chemotherapy, median (range)                  2 (1--5)
  Induction chemotherapy                                                         
   Cisplatin + Docetaxel/Carboplatine + Paclitaxel/Others                        16/12/3
  Clinical stage following chemotherapy                                          
   ⅠA/ⅠB/ⅡA/ⅡB/ⅢA                                                                3/2/1/1/24
  RECIST response                                                                
   CR/PR/SD/PD                                                                   1/19/10/1
  Time from last induction chemotherapy to date of surgery, median days, range   35 (21--68)
  Pathological stage following chemotherapy                                      
   0/IA/IB/ⅡA/ⅡB/ⅢA                                                              1/1/3/1/0/25
  Adjuvant chemotherapy                                                          
   Yes (Cisplatin + Docetaxel/Carboplatine + Paclitaxel/Others)/No               20 (5/12/3)/11
  Ef                                                                             
   1/2/3                                                                         24/3/4

###### 

The univariate analysis of the clinical and pathological characteristics associated DFI (disease-free interval) and OS (overall survival).

Table 2

  Parameter                                                  Median DFI (months)   Log-Rank *P value*   MST[a](#tbl2fna){ref-type="table-fn"} (years)   Log-Rank *P value*
  ---------------------------------------------------------- --------------------- -------------------- ----------------------------------------------- --------------------
  Gender                                                                           0.398                                                                0.487
   Male                                                      15.5                                       9.9                                             
   Female                                                    6.7                                        6.3                                             
  Age, years                                                                       0.928                                                                0.592
   ≥64 years                                                 19.8                                       6.3                                             
   \<64 years                                                12.8                                       9.3                                             
  Tumor histology                                                                  **[0.041]{.ul}**                                                     0.983
   Sq                                                        23.5                                       9.3                                             
   Non-Sq                                                    6.7                                        3.9                                             
  Tumor marker                                                                     0.288                                                                0.574
   Increase                                                  12.0                                       6.7                                             
   Decrease                                                  30.3                                       9.3                                             
  Tumor size                                                                       0.179                                                                0.503
   ≥42 mm                                                    24.9                                       9.9                                             
   \<42 mm                                                   12.2                                       6.3                                             
  The number of N2 lymph node                                                      0.284                                                                0.186
   Single                                                    9.0                                        2.4                                             
   Multiple                                                  25.0                                       9.3                                             
  Time from last induction chemotherapy to date of surgery                         0.792                                                                0.319
   ≥36 days                                                  13.0                                       6.7                                             
   \<36 days                                                 13.8                                       6.3                                             
  Induction chemotherapy                                                           0.311                                                                0.311
   Cisplatin + Docetaxel                                     22.5                                       9.3                                             
   Carboplatin + Paclitaxel                                  12.2                                       6.3                                             
   Others                                                    6.9                                        6.7                                             
  RECIST response                                                                  0.397                                                                0.293
   CR or PR                                                  25.0                                       9.3                                             
   SD                                                        11.2                                       6.7                                             
   PD                                                        10.9                                       1.2                                             
  Pathological downstaging                                                         0.282                                                                0.404
   Yes                                                       36.6                                       9.9                                             
   No                                                        11.3                                       6.3                                             
  Pathological stage                                                               0.492                                                                0.531
   ０ or Ⅰ                                                   36.6                                       10.1                                            
   Ⅱ                                                         75.7                                       6.96                                            
   Ⅲ                                                         11.2                                       6.3                                             
  Adjuvant chemotherapy                                                            0.971                                                                0.365
   Yes                                                       12.6                                       9.9                                             
   No                                                        9.0                                        2.3                                             
  Ef                                                                               0.360                                                                0.238
   1                                                         12.9                                       9.9                                             
   2                                                         6.7                                        6.3                                             
   3                                                         19.8                                       3.9                                             

MST: median survival time.
